Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Azura Ophthalmics Ltd. currently manages 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 2 distinct examiners and 2 distinct art units. This distribution shows that the company's active prosecution is split across different administrative paths within the patent office. The 2 pending office actions are split between the 2 distinct examiners involved.
The busiest examiner for the portfolio is ROMERO, KRISTEN WANG, who is handling 1 pending office action. Because the active matters are split between these officials, the company must navigate multiple examiner styles simultaneously. The presence of 2 distinct art units suggests that the company's pharmaceutical innovations span different sub-specialties within the Biotechnology & Pharmaceuticals sector.
Practitioners should prepare for varied feedback, as no single examiner or art unit controls the entirety of the pending portfolio. This diversity in prosecution requires a strategy to address the specific requirements of ROMERO, KRISTEN WANG and the other assigned official. Managing the 2 pending office actions across the different units necessitates a coordinated approach to maintain consistency in the company's patent claims.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ROMERO, KRISTEN WANG | 1 | 68.8% | +31.9% |
| HUANG, GIGI GEORGIANA | 1 | 31.8% | +30.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18033055 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | ROMERO, KRISTEN WANG | 31d overdue |
| 18119248 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | HUANG, GIGI GEORGIANA | — |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18033055 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | ROMERO, KRISTEN WANG | 1624 | DP | Non-Final OA | 31d overdue | Pending | Apr 20, 2023 |
| 18119248 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | HUANG, GIGI GEORGIANA | 1613 | §103§112DP | Final Rejection | — | Pending | Mar 08, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial